LBx Probe ALK C1156Y

Product Information
Target Mutation | p.C1156Y |
---|---|
製品番号 (旧製品番号) | A067 (65102) |
Detection | Typing |
Volume | Sufficient for 50 reactions |
Buffer | Low TE |
Storage Conditions | 4℃ |
Samples for | cfDNA, gDNA (except DNA extracted from FFPE) |
Application | Digital PCR |
Quality Control



文献・学会発表
Takeshita T. et al., Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer, Mol Cancer. 2018 Feb 26;17(1):67.PMID:29482551, DOI: 10.1186/s12943-018-0808-y
Takeshita T. et al., Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients, BMC Cancer. 2017 Nov 22;17(1):786.
PMID:29166868, DOI:10.1186/s12885-017-3779-2
Yamaoka T. et al., Distinct Afatinib Resistance Mechanisms Identified in LungAdenocarcinoma Harboring an EGFR Mutation, Mol Cancer Res. 2017 Jul;15(7):915-928.
PMID:28289161, DOI:10.1158/1541-7786.MCR-16-0482
Takeshita T. et al., Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients, Oncotarget, 2017 Jun 14;(32):52142-52155.
PMID:28881720, DOI:10.18632/oncotarget.18479